Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1977 6
1978 1
1979 6
1980 3
1981 6
1982 6
1983 1
1984 11
1985 8
1986 9
1987 16
1988 10
1989 17
1990 28
1991 14
1992 17
1993 21
1994 17
1995 11
1996 21
1997 17
1998 35
1999 36
2000 37
2001 41
2002 35
2003 50
2004 60
2005 62
2006 67
2007 88
2008 100
2009 103
2010 147
2011 143
2012 150
2013 171
2014 172
2015 183
2016 122
2017 83
2018 155
2019 164
2020 179
2021 188
2022 183
2023 145
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

2,825 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Johnson ML, et al. Among authors: mok t. J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3. J Clin Oncol. 2023. PMID: 36327426 Free PMC article. Clinical Trial.
PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC). ...PFS (HR, 0.72; 9 …
PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab …
Gasdermin E suppresses tumour growth by activating anti-tumour immunity.
Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, Sengupta S, Yao Y, Wu H, Lieberman J. Zhang Z, et al. Among authors: mok tmy. Nature. 2020 Mar;579(7799):415-420. doi: 10.1038/s41586-020-2071-9. Epub 2020 Mar 11. Nature. 2020. PMID: 32188940 Free PMC article.
GSDME expression enhances the phagocytosis of tumour cells by tumour-associated macrophages, as well as the number and functions of tumour-infiltrating natural-killer and CD8(+) T lymphocytes. Killer-cell granzyme B also activates caspase-independent pyroptosis in target c …
GSDME expression enhances the phagocytosis of tumour cells by tumour-associated macrophages, as well as the number and functions of tumour-i …
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer.
Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, Huang M, Yi X, Liang M, Wang Y, Shen H, Tong R, Wang W, Li L, Song J, Li J, Su X, Ding Z, Gong Y, Zhu J, Wang Y, Zou B, Zhang Y, Li Y, Zhou L, Liu Y, Yu M, Wang Y, Zhang X, Yin L, Xia X, Zeng Y, Zhou Q, Ying B, Chen C, Wei Y, Li W, Mok T. Lu Y, et al. Among authors: mok t. Nat Med. 2020 May;26(5):732-740. doi: 10.1038/s41591-020-0840-5. Epub 2020 Apr 27. Nat Med. 2020. PMID: 32341578 Clinical Trial.
Primary endpoints were safety and feasibility, and the secondary endpoint was efficacy. The exploratory objectives included tracking of edited T cells. All prespecified endpoints were met. PD-1-edited T cells were manufactured ex vivo by cotransfection using electro …
Primary endpoints were safety and feasibility, and the secondary endpoint was efficacy. The exploratory objectives included tracking of edit …
Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases.
Cho SI, Lee S, Mok YG, Lim K, Lee J, Lee JM, Chung E, Kim JS. Cho SI, et al. Among authors: mok yg. Cell. 2022 May 12;185(10):1764-1776.e12. doi: 10.1016/j.cell.2022.03.039. Epub 2022 Apr 25. Cell. 2022. PMID: 35472302 Free article.
Bacterial cytidine deaminase DddA-derived cytosine base editors (DdCBEs) enabling mtDNA editing, however, are largely limited to C-to-T conversions in the 5'-TC context (e.g., TC-to-TT conversions), suitable for generating merely 1/8 of all possible transition (purine-to-p …
Bacterial cytidine deaminase DddA-derived cytosine base editors (DdCBEs) enabling mtDNA editing, however, are largely limited to C-to-T …
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, Martinez-Picado J, Nijhuis M, Wensing AMJ, Lee H, Grant P, Nastouli E, Lambert J, Pace M, Salasc F, Monit C, Innes AJ, Muir L, Waters L, Frater J, Lever AML, Edwards SG, Gabriel IH, Olavarria E. Gupta RK, et al. Among authors: mok hp. Nature. 2019 Apr;568(7751):244-248. doi: 10.1038/s41586-019-1027-4. Epub 2019 Mar 5. Nature. 2019. PMID: 30836379 Free PMC article.
Plasma HIV-1 RNA has been undetectable at less than one copy per millilitre along with undetectable HIV-1 DNA in peripheral CD4 T lymphocytes. Quantitative viral outgrowth assays from peripheral CD4 T lymphocytes show no reactivatable virus using a total of 24 milli …
Plasma HIV-1 RNA has been undetectable at less than one copy per millilitre along with undetectable HIV-1 DNA in peripheral CD4 T lym …
The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.
Chalmers SA, Ayilam Ramachandran R, Garcia SJ, Der E, Herlitz L, Ampudia J, Chu D, Jordan N, Zhang T, Parodis I, Gunnarsson I, Ding H, Shen N, Petri M, Mok CC, Saxena R, Polu KR, Connelly S, Ng CT, Mohan C, Putterman C. Chalmers SA, et al. Among authors: mok cc. J Clin Invest. 2022 Jan 4;132(1):e147334. doi: 10.1172/JCI147334. J Clin Invest. 2022. PMID: 34981775 Free PMC article.
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). ...ALCAM was expressed by renal structural cells whereas CD6 expression was exclusive to T cells, with elevated numbers of CD6+ and ALCAM+ c …
T cells are central to the pathogenesis of lupus nephritis (LN), a common complication of systemic lupus erythematosus (SLE). ...ALCA …
CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA.
Mok BY, Kotrys AV, Raguram A, Huang TP, Mootha VK, Liu DR. Mok BY, et al. Nat Biotechnol. 2022 Sep;40(9):1378-1387. doi: 10.1038/s41587-022-01256-8. Epub 2022 Apr 4. Nat Biotechnol. 2022. PMID: 35379961 Free PMC article.
DdCBEs containing evolved DddA11 offered a broadened HC (H = A, C or T) sequence compatibility for both mitochondrial and nuclear base editing, increasing average editing efficiencies at AC and CC targets from less than 10% for canonical DdCBE to 15-30% and up to 50% in ce …
DdCBEs containing evolved DddA11 offered a broadened HC (H = A, C or T) sequence compatibility for both mitochondrial and nuclear bas …
Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2.
Liu D, Chen C, Chen D, Zhu A, Li F, Zhuang Z, Mok CKP, Dai J, Li X, Jin Y, Chen Z, Sun J, Wang Y, Li Y, Zhang Y, Wen L, Zhang Z, Zhuo J, Wang J, Ran W, Wang D, Zhang S, Tang Y, Li S, Lai X, Wei P, Yuan J, Chen F, Huang S, Sun F, Qian Z, Tan W, Zhao J, Peiris M, Zhao J. Liu D, et al. Among authors: mok ckp. Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2202820120. doi: 10.1073/pnas.2202820120. Epub 2023 Jan 18. Proc Natl Acad Sci U S A. 2023. PMID: 36652473 Free PMC article.
The recent emergence of COVID-19 and the possible cross-reactive antibody and T cell responses between these CCCoV and SARS-CoV-2 emphasize the need to develop experimental animal models for CCCoV. ...Ad5-hAPN- and Ad5-hACE2-sensitized mice generated virus-specific T …
The recent emergence of COVID-19 and the possible cross-reactive antibody and T cell responses between these CCCoV and SARS-CoV-2 emp …
Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver.
Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, Zhang L, Liang Z, Liu X, Xiong Z, Zeng X, Wang J, Lu J, Li J, Sun H, Tian X, Yeung PC, Hou Y, Lee HM, Lam CCH, Leung HHW, Chan AWH, To KF, Wong J, Lai PBS, Ng KKC, Wong SKH, Wong VWS, Kong APS, Sung JJY, Cheng ASL. Tang W, et al. Among authors: mok mts. Cell Mol Immunol. 2022 Jul;19(7):834-847. doi: 10.1038/s41423-022-00872-3. Epub 2022 May 20. Cell Mol Immunol. 2022. PMID: 35595819 Free PMC article.
Using high-fat high-carbohydrate diet-associated orthotopic and spontaneous NAFLD-HCC mouse models, we found that hepatic cholesterol accumulation in obesity selectively suppressed natural killer T (NKT) cell-mediated antitumor immunosurveillance. Transcriptome analysis of …
Using high-fat high-carbohydrate diet-associated orthotopic and spontaneous NAFLD-HCC mouse models, we found that hepatic cholesterol accumu …
2,825 results